Nephros
Nephros' revenue rose 32.7% to $19 million in fiscal 2025. Its operating margin was 6.1%, up from 0.0% a year earlier. The diluted share count rose 3.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
From fiscal 2024 to 2025, earnings per share grew 1,000.0% a year and net income 1,100.0% a year, as new shares raised the share count by 4% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 7 | 4 | 4 | 4 | 5 |
| Debt incl. finance leases | 0 | 0 | — | — | — |
| Net debt (negative means net cash) | −7 | −4 | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.0x | — | — | — |
| Interest coverage | −79.3x | −216.8x | −796.5x | 6.0x | 1,146.0x |
| Current ratio | 5.7x | 5.8x | 4.0x | 5.3x | 4.1x |
| Quick ratio | 3.8x | 3.6x | 2.8x | 3.6x | 2.9x |
Cash flow
Projections
Project Nephros' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $22,075 of Nephros shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 17, 2026 | Arthur H AmronDirector | Bought | 2,500 | $2.84 | $7,100 | Form 4 |
| Nov 16, 2026 | Arthur H AmronDirector | Bought | 5,000 | $3.00 | $14,975 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 48.0% | −4.4% | — |
| Altman Z'' | −34.61 | −34.59 | −26.46 |
| Accruals ratio | −21.0% | 4.9% | −3.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Pass | Pass |
| Cash from operations is positive | Pass | Fail | Pass |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Fail | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Pass |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | — | — | — |
Compare
Put Nephros side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Nephros | FY25 | 32.7% | 6.1% | — | — | — | — | |
| QT Imaging Holdings | FY25 | 287.9% | −23.4% | −48.0% | −130.7% | — | 4 | Compare |
| Spectral AI | FY25 | −33.6% | −43.8% | — | — | — | — | Compare |
| Vivos Therapeutics | FY25 | 16.1% | −114.0% | −100.9% | — | — | 3 | Compare |
| Jin Medical International | FY25 | −12.0% | 2.9% | −18.0% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 2 | 4 | 6 | 10 | 9 | 10 | 10 | 14 | 14 | 19 |
| Revenue growth | 19.3% | 64.2% | 49.3% | 81.7% | −17.2% | 19.3% | −2.4% | 42.7% | −0.5% | 32.7% |
| Gross profit | 1 | 2 | 3 | 6 | 5 | 6 | 5 | 8 | 9 | 12 |
| Research and development | 1 | 1 | 2 | 3 | 3 | 2 | 1 | 1 | 1 | 1 |
| Operating income | −3 | −2 | −3 | −3 | −4 | −3 | −4 | −2 | 0 | 1 |
| Net income | −3 | −1 | −3 | −3 | −4 | −4 | −7 | −2 | 0 | 1 |
| Diluted EPS (US$) | −0.06 | −0.02 | −0.50 | −0.45 | −0.52 | −0.41 | −0.73 | −0.15 | 0.01 | 0.11 |
| Diluted shares (millions) | 49 | 53 | 7 | 8 | 9 | 10 | 10 | 10 | 11 | 11 |
| Cash flow | ||||||||||
| Cash from operations | −2 | −0 | −4 | −2 | −7 | −1 | −3 | 1 | −0 | 2 |
| Capital expenditure | 0 | — | — | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Free cash flow | −2 | — | — | −2 | −7 | −1 | −3 | 1 | −1 | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 0 | 2 | 5 | 4 | 8 | 7 | 4 | 4 | 4 | 5 |
| Debt incl. finance leases | 1 | 1 | 1 | 1 | 1 | 0 | 0 | — | — | — |
| Total assets | 3 | 5 | 11 | 12 | 18 | 18 | 11 | 12 | 11 | 14 |
| Total liabilities | 2 | 3 | 4 | 4 | 3 | 3 | 2 | 4 | 3 | 3 |
| Shareholders' equity | 1 | 2 | 4 | 5 | 12 | 12 | 6 | 8 | 9 | 10 |
| Margins and ratios | ||||||||||
| Gross margin | 55.8% | 60.2% | 56.3% | 58.9% | 57.4% | 55.1% | 47.4% | 59.0% | 61.6% | 61.9% |
| Operating margin | −123.7% | −58.4% | −53.0% | −30.5% | −49.9% | −31.8% | −43.5% | −11.2% | 0.0% | 6.1% |
| Net margin | −130.7% | −21.2% | −59.8% | −30.8% | −52.9% | −37.9% | −71.2% | −11.1% | 0.5% | 6.3% |
| Free cash flow margin | −93.0% | — | — | −22.2% | −83.4% | −14.2% | −33.8% | 5.3% | −3.9% | — |
| Rule of 40 (growth + FCF margin) | −73.6% | — | — | 59.5% | −100.6% | 5.1% | −36.2% | 48.0% | −4.4% | — |
| Return on capital | — | −181.3% | −120.2% | −65.6% | −54.9% | −31.9% | −50.8% | — | — | — |
| Return on equity | — | −61.8% | −118.4% | −75.0% | −52.6% | −31.9% | −82.2% | −22.6% | 0.9% | 12.7% |
| Return on assets | −91.2% | −21.1% | −43.8% | −28.7% | −30.0% | −21.4% | −49.6% | −13.8% | 0.6% | 9.6% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |